Fasting insulin blood test
Insulin (fasting). Also called: Insulin, Serum insulin, Insulin, fasting
Fasting insulin is the insulin in your blood after an overnight fast. Labcorp prints 2.6-24.9 µIU/mL; Quest flags above 18.4 as high. A high value with normal glucose usually means the body is compensating for insulin resistance.
Looking for the injectable peptide? See Insulin.
At a glance
| What it measures | The insulin in your blood after an overnight fast: how much the pancreas needs to release to keep fasting glucose steady. |
|---|---|
| Sample | Serum. A fasting sample is required at Labcorp and Quest. |
| Adult ranges | Labcorp 2.6-24.9 µIU/mL; Quest optimal 18.4 or lower, high above 18.4. |
| Peptides that move it | Lowered by Tirzepatide, and by Semaglutide in people without diabetes; raised by Dulaglutide in type 2 diabetes. |
| Lab code | LOINC 20448-7; fasting 27873-9 (Labcorp 004333, Quest 561) |
What is Fasting insulin?
Insulin is the hormone the pancreas releases to move glucose into cells. Fasting insulin is measured after an overnight fast, when glucose and insulin settle into a steady feedback loop. When the body becomes resistant to insulin, the pancreas releases more to keep glucose normal, so a high fasting insulin can appear years before glucose rises.
How it is made and regulated
Where it is made
Beta cells in the pancreas release insulin in response to glucose. In the fasting state, glucose and insulin are held in balance by a simple feedback loop, which is what the HOMA model describes.
Sources: [1]
What controls it
Insulin resistance pushes fasting insulin up: in people with impaired glucose tolerance or type 2 diabetes, and in about 25% of non-obese people with normal glucose tolerance, the beta cells keep glucose normal only by maintaining chronically high insulin. When they can no longer do so, glucose rises.
Sources: [2]
How it travels in the blood
Labs measure insulin by immunoassay: Labcorp uses a two-site electrochemiluminescence assay on the Roche cobas platform. Results differ between platforms, so reference intervals are platform specific. The test is valid in people who do not take insulin or who take unmodified human insulin.
How long it lasts
Fasting insulin changes with eating, so both labs require a fasting sample. On treatment it can move within weeks: on tirzepatide it rose at week 8 before falling as the dose increased.
What it does
In type 2 diabetes, insulin levels may look normal or high at first, but they are too low for the glucose level, because insulin secretion is failing against a background of insulin resistance. That is why the ADA diagnoses diabetes from glucose and A1C rather than insulin.
Sources: [7]
Reference ranges
There is no guideline cut-off for fasting insulin. Each lab prints its own interval: Labcorp 2.6-24.9 µIU/mL and Quest 18.4 or lower, from Quest's own 2022 reference-interval studies.
Labcorp (test 004333)
| Group | Range (µIU/mL) |
|---|---|
| Fasting adults | 2.6-24.9 |
As printed on Labcorp's test page and sample report for test 004333. Values above 24.9 are flagged high and below 2.6 low.
Quest Diagnostics (test 561)
| Group | Range (µIU/mL) |
|---|---|
| Optimal | 18.4 or lower |
| High | above 18.4 |
Read from Quest's test directory for the East service area. Quest bases the adult cut points on its own 2022 insulin reference-interval studies and lists no moderate band.
Insulin assays differ by platform, so compare results from the same lab.
Units: Labs outside the US often report insulin in pmol/L. Multiply µIU/mL by about 6, from insulin's biological activity of 6.00 nmol per IU; some analyzers use 6.945 instead, which reads 15-20% higher. [4]
Is there an "optimal" range?
Fasting insulin has no agreed target; labs and guidelines treat it differently.
The lab interval
2.6-24.9 µIU/mL
Labcorp
The range printed on Labcorp reports for a fasting sample.
Sources: [8]
A tighter "optimal" cut-off
18.4 µIU/mL or lower
Quest Diagnostics
Quest prints 18.4 or lower as optimal, based on its own 2022 studies.
Sources: [5]
No insulin target at all
Diagnosis by glucose and A1C
American Diabetes Association (2026)
Insulin can look normal or high early in type 2 diabetes, so the ADA does not use it to diagnose diabetes.
Sources: [7]
What raises it
| Factor | How | How much |
|---|---|---|
| Insulin resistanceCondition | The pancreas compensates by releasing more insulin to keep glucose normal. | No published magnitude [2] |
| Early type 2 diabetesCondition | Insulin can look normal or high before secretion fails. | No published magnitude [7] |
| Insulin-releasing drugs in type 2 diabetesPeptide | Dulaglutide stimulates insulin release and raised fasting insulin in its monotherapy trial. | +35.38 pmol/L on 0.75 mg at 26 weeks [9] |
| Growth hormone-releasing peptidesPeptide | Tesamorelin and Sermorelin raised fasting insulin in some studies. | +35% on tesamorelin in older adults with mild cognitive impairment [10] [11] |
What lowers it
| Factor | How | How much |
|---|---|---|
| Weight loss on Tirzepatide or SemaglutidePeptide | Tirzepatide and Semaglutide lowered fasting insulin in their trials. | -20.9% on tirzepatide 15 mg at 40 weeks [6] [12] |
| IGF-1 injectionsPeptide | Recombinant IGF-1 (Insulin-Like Growth Factor 1) lowered fasting insulin in a short study in type 2 diabetes. | 13 to 5 microU/mL over 7 days [13] |
Peptides that affect Fasting insulin
How each peptide in our library changes fasting insulin, from the FDA label and published trials. Results depend on who is treated: in type 2 diabetes, drugs that stimulate insulin release can raise fasting insulin, while in people without diabetes weight loss lowers it. Only the Trulicity label reports fasting insulin. Injected Insulin is not listed here: the test measures human insulin, so results on insulin treatment reflect the dose. No study has measured fasting insulin after repeated dosing with Retatrutide, Lixisenatide, CJC-1295, Ipamorelin, Mod GRF 1-29, GHRP-2, GHRP-6, MOTS-c or 5-Amino-1MQ; PubMed searches for each find no human dosing data (the MOTS-c studies measure the body's own MOTS-c, and the GHRP-6 work is a single infusion under growth-hormone blockade).
| Peptide | Effect on Fasting insulin | Size of effect | Evidence |
|---|---|---|---|
| Sermorelin | Raises | No figure in the abstract: in 18 children with short stature given sermorelin 20 micrograms/kg twice daily for one year, fasting blood glucose and insulin levels increasedA rise in one small study in children. [11] | Human trials |
| Exenatide | Lowers | 12 children and adolescents with extreme obesity, 3 months (crossover vs lifestyle alone): fasting insulin -7.5 mU/l vs controlOne small pilot trial in young people with severe obesity. [14] | Human trials |
| IGF-1 (Insulin-Like Growth Factor 1) | Lowers | 8 people with poorly controlled type 2 diabetes, recombinant IGF-1 80 micrograms/kg twice daily for 7 days: fasting insulin 13 to 5 microU/mL; no control groupShort-term IGF-1 injections cut fasting insulin sharply in a small study. [13] | Human trials |
| Liraglutide | Lowers | No figure in an open source: in adults with obesity and prediabetes randomized to liraglutide for 14 weeks, liraglutide decreased insulin and improved HOMA-IR within 2 weeks, before weight lossThe direction is reported; the size is not in an open source. [15] | Human trials |
| SemaglutideObesity without diabetes | Lowers | Adolescents with obesity, 2.4 mg, 68 weeks (193 participants): fasting serum insulin -33.6% vs -10.1% on placebo. In adults (STEP 1) it fell more than on placebo (p ≤ .001)Fasting insulin falls with weight loss on semaglutide in people without diabetes. [12] [16] | Human trials |
| SurvodutideOverweight or obesity | Lowers | No figure in the abstract: in a phase 2 trial in adults with overweight or obesity, survodutide lowered fasting insulin significantly vs placeboLower fasting insulin vs placebo, largely tracking weight loss. [17] | Human trials |
| Tirzepatide | Lowers | Type 2 diabetes, 40 weeks (1879 participants): fasting insulin -8.9% on 5 mg, -14.6% on 10 mg and -20.9% on 15 mg vs +0.6% on semaglutide 1 mgA dose-related fall in type 2 diabetes, after a brief rise early in treatment. [6] [18] | Human trials |
| Hexarelin | No clear effect | Measured, no change: 11 healthy young adults, single dose; insulin and glucose did not changeSingle-dose data only; no repeated-dosing study. [19] | Human trials |
| MK-677 (Ibutamoren) | No clear effect | Measured, no change: fasting insulin was unchanged after 2 months in obese adults. Over 12 months in healthy older adults (25 mg/day), insulin sensitivity estimated from fasting insulin and glucose fell and fasting glucose rose 0.3 mmol/LFasting insulin held steady short term, but insulin sensitivity fell over a year. [20] [21] | Human trials |
| SemaglutideType 2 diabetes | No clear effect | Type 2 diabetes, 1 mg, 40 weeks: fasting insulin +0.6% from baselineIn type 2 diabetes fasting insulin barely changed on semaglutide 1 mg. [6] | Human trials |
| SurvodutideType 2 diabetes | No clear effect | No figure in the abstract: in a 16-week phase 2 trial in 413 adults with type 2 diabetes on metformin, fasting insulin did not change significantlyNo significant change in type 2 diabetes. [17] | Human trials |
| Tesamorelin | Unclear | Older adults, 1 mg/day for 20 weeks (152 randomized): fasting insulin rose 35%, within the normal range, in those with mild cognitive impairment. People with HIV, 2 mg/day for 26 weeks (412 randomized): no significant differences in glycemic measures, which included insulinA rise in one older-adult trial; no significant change in the HIV trial. [10] [22] | Human trials |
| Dulaglutide | Raises | Type 2 diabetes, monotherapy trial, 26 weeks: fasting insulin rose 35.38 pmol/L on 0.75 mg and 17.50 pmol/L on 1.5 mg from baselineIn type 2 diabetes dulaglutide raises fasting insulin, as expected of a drug that stimulates insulin release. [9] | FDA label |
What high or low results can mean
A high result
Above 24.9 µIU/mL on Labcorp's interval, or above 18.4 on Quest's, is high. A high fasting insulin with normal glucose usually means the pancreas is compensating for insulin resistance.
- Insulin resistance
- Obesity
- Early type 2 diabetes
- An insulin-secreting tumor (rare)
A low result
Below 2.6 µIU/mL is flagged low by Labcorp. Low insulin with high glucose points to too little insulin production, as in type 1 diabetes.
- Type 1 diabetes
- Loss of beta-cell function
How the test works
| Sample | Serum: 1 mL at Quest; a red-top or gel-barrier tube at Labcorp. |
|---|---|
| Fasting | Both labs require a fasting sample. |
| Timing | No guideline recommends routine fasting-insulin testing; the ADA diagnoses diabetes with glucose and A1C. It is ordered to look for insulin resistance, usually with fasting glucose. |
| Lab differences | Immunoassay: electrochemiluminescence on the Roche cobas at Labcorp. Platforms differ; one widely used analyzer converts units with 6.945 instead of 6.00 and reads 15-20% higher. |
| Retesting | Compare results from the same lab, because insulin assays differ between platforms. |
| Labcorp order code | 004333: Insulin |
| Quest Diagnostics order code | 561: Insulin |
| LOINC codes |
|
History
Measuring insulin in blood became possible in 1960, and the idea that high insulin signals resistance followed.
- 1960Yalow and Berson publish an immunoassay for insulin in human plasma. [23]
- 1985Matthews and colleagues describe HOMA, estimating insulin resistance from fasting glucose and insulin. [1]
- 1988Reaven's Banting lecture describes insulin resistance with compensatory high insulin as a cause of disease. [2]
FAQ
What is a normal fasting insulin?
Labcorp prints 2.6-24.9 µIU/mL. Quest prints 18.4 µIU/mL or lower as optimal and above 18.4 as high.
Do I need to fast for an insulin test?
Yes. Both Labcorp and Quest require a fasting sample.
Is fasting insulin used to diagnose diabetes?
No. The ADA diagnoses diabetes with glucose and A1C. Insulin can look normal or high early in type 2 diabetes.
Sources: [7]
What does high insulin with normal glucose mean?
Usually that your body is compensating for insulin resistance by releasing more insulin to keep glucose normal.
Sources: [2]
How does fasting insulin relate to HOMA-IR?
HOMA-IR multiplies fasting insulin (µIU/mL) by fasting glucose (mmol/L) and divides by 22.5. It turns the two numbers into one estimate of insulin resistance.
Sources: [24]
Why do labs report insulin in different units?
US labs use µIU/mL; others use pmol/L. Multiply by about 6 to convert. Some analyzers use 6.945 instead, which reads 15-20% higher.
Sources: [4]
Which peptides lower fasting insulin?
In trials, Tirzepatide lowered it 20.9% at 15 mg in type 2 diabetes, Semaglutide by 33.6% vs 10.1% on placebo in adolescents with obesity, and Exenatide by 7.5 mU/l vs lifestyle alone in young people with severe obesity.
Why does dulaglutide raise insulin?
It stimulates insulin release. In its monotherapy trial in type 2 diabetes, fasting insulin rose 35.38 pmol/L on 0.75 mg and 17.50 pmol/L on 1.5 mg.
Sources: [9]
Do growth hormone peptides affect insulin?
Tesamorelin raised fasting insulin 35% in older adults with mild cognitive impairment, and Sermorelin raised it in children. On MK-677 (Ibutamoren) fasting insulin was unchanged at 2 months, but insulin sensitivity fell over a year.
Does the test work if I take insulin?
Only partly. Labcorp's assay is valid in people not taking insulin or taking unmodified human insulin; injected insulin adds to the result.
Sources: [3]
References
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. PMID 3899825
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. PMID 3056758
- Labcorp. Test 004333: Insulin. Methodology, specimen, patient preparation, reference range, limitations and LOINC map. labcorp.com/tests/004333/insulin
- Larsen PB, Linneberg A, Hansen T, et al. Reference intervals for C-peptide and insulin derived from a general adult Danish population. Clin Biochem. 2017;50(7-8):408-413. PMID 27989491
- Quest Diagnostics. Test 561: Insulin. Test directory: methodology, specimen, patient preparation, LOINC and risk categories. testdirectory.questdiagnostics.com/test/test-detail/561/insulin?cc=PHP
- Frias JP, De Block C, Brown K, et al. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). J Clin Endocrinol Metab. 2024;109(7):1745-1753. PMID 38252888
- American Diabetes Association Professional Practice Committee for Diabetes* . 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S27-S49. PMID 41358893
- Labcorp. Sample report, test 004333 (Insulin): reference interval as printed for a fasting specimen (reported 11/19/2016). files.labcorp.com/testmenu-d8/sample_reports/004333.pdf
- Trulicity (dulaglutide) injection. FDA prescribing information: Clinical Pharmacology (fasting insulin and C-peptide in the monotherapy trial). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9. PMID 22869065
- Kirk JM, Trainer PJ, Majrowski WH, et al. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. Clin Endocrinol (Oxf). 1994;41(4):487-93. PMID 7955460
- Arslanian S, Gies I, Goldman B, et al. Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. Diabetes Care. 2026;49(6):954-962. PMID 41296499
- Cusi K, DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab. 2000;85(9):3077-84. PMID 10999789
- Kelly AS, Metzig AM, Rudser KD, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring). 2012;20(2):364-70. PMID 22076596
- Mashayekhi M, Nian H, Mayfield D, et al. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Diabetes. 2024;73(1):38-50. PMID 37874653
- Kosiborod MN, Bhatta M, Davies M, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023;25(2):468-478. PMID 36200477
- Ekinci EI, Maldonado SG, Unseld A, et al. Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. Diabetes Obes Metab. 2026;28(9):8242-8253. PMID 42331726
- Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396. PMID 33236115
- Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86(10):5083-6. PMID 11600590
- Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-9. PMID 9467542
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. PMID 18981485
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PMID 18057338
- YALOW RS, BERSON SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960;39(7):1157-75. PMID 13846364
- Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:47. PMID 24131857
Educational information, not medical advice. Lab ranges and test codes were checked on November 2, 2026. Always use the range printed on your own report, and talk to a clinician about your results.